Literature DB >> 22387007

Increased proteinase inhibitor-9 (PI-9) and reduced granzyme B in lung cancer: mechanism for immune evasion?

Cyd Soriano1, Violet Mukaro, Greg Hodge, Jessica Ahern, Mark Holmes, Hubertus Jersmann, David Moffat, David Meredith, Craig Jurisevic, Paul N Reynolds, Sandra Hodge.   

Abstract

Cytotoxic CD8(+) T-cells mount immune responses to cancer via cytotoxic pathways including granzyme B. Cancer cells are also known to develop immune evasion mechanisms. We hypothesised that lung cancer cells would over-express the granzyme B-inhibitor, proteinase inhibitor-9 (PI-9) and down-regulate granzyme B expression by neighbouring CD8(+) T-cells. We investigated PI-9 expression in lung cancer cell lines, and primary lung cancer cells obtained at curative lung resection from cancer patients with/without chronic obstructive pulmonary disease (COPD). Granzyme B and PI-9 expression was also determined in CD8(+) T-cells from the cancer and non-cancer areas of resected lung tissue and from bronchoalveolar lavage (BAL). We then evaluated the effects of conditioned media from lung cancer cell lines on granzyme B expression and the cytotoxic activity of CD8(+) T-cells. PI-9 was highly expressed in lung cancer cell lines. Increased PI-9 expression was also observed in primary cancer cells vs. epithelial cells from non-cancer tissue or bronchial brushing-derived normal primary large airway epithelial cells. Expression significantly correlated with cancer stage. Significantly reduced granzyme B was noted in CD8(+) T-cells from cancer vs. non-cancer tissue. Granzyme B production by CD8(+) T-cells was reduced in the presence of conditioned media from lung cancer cell lines. Our data suggest that lung cancer cells utilise their increased PI-9 expression to protect from granzyme B-mediated cytotoxicity as an immune evasion mechanism, a function that increases with lung cancer stage.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387007     DOI: 10.1016/j.lungcan.2012.01.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  15 in total

Review 1.  COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link.

Authors:  Steven Bozinovski; Ross Vlahos; Desiree Anthony; Jonathan McQualter; Gary Anderson; Louis Irving; Daniel Steinfort
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

2.  Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells.

Authors:  G Hodge; J Barnawi; C Jurisevic; D Moffat; M Holmes; P N Reynolds; H Jersmann; S Hodge
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

3.  Transcriptome analysis in prenatal IGF1-deficient mice identifies molecular pathways and target genes involved in distal lung differentiation.

Authors:  Rosete Sofía Pais; Nuria Moreno-Barriuso; Isabel Hernández-Porras; Icíar Paula López; Javier De Las Rivas; José García Pichel
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

4.  Zinc and zinc transporters in macrophages and their roles in efferocytosis in COPD.

Authors:  Rhys Hamon; Claire C Homan; Hai B Tran; Violet R Mukaro; Susan E Lester; Eugene Roscioli; Mariea D Bosco; Chiara M Murgia; Margaret Leigh Ackland; Hubertus P Jersmann; Carol Lang; Peter D Zalewski; Sandra J Hodge
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

Review 5.  Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.

Authors:  Anna Bochicchio; Sandra Jordaan; Valeria Losasso; Shivan Chetty; Rodrigo Casasnovas Perera; Emiliano Ippoliti; Stefan Barth; Paolo Carloni
Journal:  Biomedicines       Date:  2017-02-17

6.  CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function.

Authors:  Xi Chen; Qianqian Shao; Shengnan Hao; Zhonghua Zhao; Yang Wang; Xiaofan Guo; Ying He; Wenjuan Gao; Haiting Mao
Journal:  Oncotarget       Date:  2017-02-21

7.  Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model.

Authors:  S Schiffer; H P Hansen; G Hehmann-Titt; M Huhn; R Fischer; S Barth; T Thepen
Journal:  Blood Cancer J       Date:  2013-03-22       Impact factor: 11.037

8.  Defective lung macrophage function in lung cancer ± chronic obstructive pulmonary disease (COPD/emphysema)-mediated by cancer cell production of PGE2?

Authors:  Francis C Dehle; Violet R Mukaro; Craig Jurisevic; David Moffat; Jessica Ahern; Greg Hodge; Hubertus Jersmann; Paul N Reynolds; Sandra Hodge
Journal:  PLoS One       Date:  2013-04-26       Impact factor: 3.240

9.  The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD.

Authors:  Greg Hodge; Mark Holmes; Hubertus Jersmann; Paul N Reynolds; Sandra Hodge
Journal:  Respir Res       Date:  2013-06-03

10.  Early synergistic interactions between the HPV16‑E7 oncoprotein and 17β-oestradiol for repressing the expression of Granzyme B in a cervical cancer model.

Authors:  J Antonio Munguía-Moreno; José Díaz-Chavéz; Enrique García-Villa; M Estela Albino-Sanchez; Daniel Mendoza-Villanueva; Rodolfo Ocadiz-Delgado; José Bonilla-Delgado; Armando Marín-Flores; Enoc M Cortés-Malagón; Elizabeth Alvarez-Rios; Alfredo Hidalgo-Miranda; Aykut Üren; Haydar Çelik; Paul F Lambert; Patricio Gariglio
Journal:  Int J Oncol       Date:  2018-06-06       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.